a public good project by the
Synthesis
Company
of California

© 2026

Helge Täubert | doi.page

0 works0 citations0 h-index

Helge Täubert

Friedrich-Alexander-Universität Erlangen-Nürnberg(DE)Universitätsklinikum Erlangen(DE)Comprehensive Cancer Center Erlangen(DE)

Publications by Year

Research Areas

Bladder and Urothelial Cancer Treatments, Cancer-related Molecular Pathways, Sarcoma Diagnosis and Treatment, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers

Most-Cited Works

→ A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans(2004)1,273 cited
→ Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival(2009)443 cited
→ MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner(2006)287 cited
→ The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes(2019)231 cited
→ Alternative and aberrant splicing of MDM2 mRNA in human cancer(2002)190 cited
→ Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma(2007)154 cited

→ Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma(2006)138 cited

→ The stem cell-associated Hiwi gene in human adenocarcinoma of the pancreas: expression and risk of tumour-related death(2008)129 cited

→ Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53(2004)111 cited

→ Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab(2018)102 cited